Ruosha Li

Professor

The University of Texas Health Science Center at Houston
Country flagUnited States
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (3)

Background and Aims The randomized CENTURY trial tested the hypothesis that a comprehensive strategy integrating intense lifestyle modification and aggressive medical management to goals with revascularization reserved for severely reduced coronary flow capacity (CFC) by positron emission tomography (PET) would reduce risk factors, subsequent revascularization, death and myocardial infarction (MI) compared with standard of care in chronic stable coronary artery disease (CAD). Methods Participants were randomly assigned to standard or comprehensive care groups. Rest-stress PET quantified CFC for physiological CAD severity at baseline, 2, 5, and up to 11 years. The comprehensive care group reviewed PET results with frequent clinic visits and open 24/7 phone/email support. Standard care lacked supportive contact with blinded PET results that were unblinded only for severely reduced CFC with high mortality risk for potential revascularization. Results Between 2009–2017, 515 patients were assigned to comprehensive care and 513 to standard care and followed for 5 or more years. Comprehensive vs standard care decreased risk factors and summed 5-year risk score (Δ−1.1 vs + 0.33; 95% confidence interval −1.84 to −0.97; P < .0001), decreased cumulative 11-year all-cause death (4.7% vs 8.2%; P = .023), death or MI (7.0% vs 11.1%; P = .024) late revascularization (9.5% vs 14.8%; P = .021) and major adverse cardiac events (20.5% vs 29.9%; P = .0006). Only 56 of 1028 (5.4%) CENTURY patients with chronic CAD had revascularization within 90 days predominantly guided by CFC severity. Conclusions The randomized CENTURY trial demonstrates that comprehensive integrated lifestyle modification and medical management towards goals with revascularization reserved for severely reduced CFC, significantly reduced risk factor scores, death, death or MI, and revascularization. ClinicalTrials.gov NCT00756379

Year:

2025

Firearm violence is a leading cause of injury and mortality in the United States. Hospital-based violence intervention programs (HVIPs) are a promising public health strategy designed to reduce recurrent violence by engaging patients during hospitalization and connecting them to support services after discharge. This protocol describes the design and implementation of the Houston Hospital-Based Violence Intervention Program (Houston-HVIP), which will be evaluated by a randomized controlled trial conducted at a Level 1 trauma center in Houston, Texas. The study plans to enroll individuals aged 16 to 35 who present with gunshot wounds (GSW) at the Level 1 trauma center. Participants are randomized to either a treatment group receiving six months of intensive case management with direct referrals to social services or a control group receiving usual care, which involves indirect referral and limited case management. The primary outcome is a composite measure of an individual’s exposure to firearm violence via (a) self-report, (b) hospital admission records, and (c) mortality records. Secondary outcomes measured at the individual level assess violent reinjury, attitudes toward violence, post-traumatic stress, aggression, and self-rated health. Outcomes are assessed at baseline and 3-, 6-, 9-, and 12-months post-enrollment. The study will enroll 274 participants and include both quantitative and qualitative assessments to evaluate program impact and participant experience. This protocol aims to contribute to the design and implementation of HVIPs in large Level 1 trauma centers.

Year:

2025

With the advancement of medical treatments, many historically incurable diseases have become curable. An accurate estimation of the cure rates is of great interest. When there are no clear biomarker indicators for cure, the estimation of cure rate is intertwined with and influenced by the specification of hazard functions for uncured patients. Consequently, the commonly used proportional hazards (PH) assumption, when violated, may lead to biased cure rate estimation. Meanwhile, longitudinal biomarker measurements for individual patients are usually available. To accommodate non-PH functions and incorporate individual longitudinal biomarker trajectories, we propose a new joint model for cure, survival, and longitudinal data, with hazard ratios between different covariate subgroups flexibly varying over time. The proposed joint model has individual random effects shared between its longitudinal and cure-survival submodels. The regression parameters are estimated by maximization of the non-parametric likelihood via the Monte Carlo expectation-maximization algorithm. The standard error estimation applies a jackknife resampling method. In simulation studies, we consider crossing and non-crossing survival curves, and the proposed model provides unbiased estimates for the cure rates. Our proposed joint cure model is illustrated via a study of chronic myeloid leukemia.

Year:

2025

Collaborators (9)

Mary Aitken

Professor and Chair

The University of Texas Health Science Center at Houston

UNITED STATES
View details

Jagat Narula

-

UNITED STATES
View details

Alexander Testa

Associate Professor and Blair Justice, Ph.D. Professorship in Mind-Body Medicine and Public Health

University of Texas at San Antonio

UNITED STATES
View details

Sandra McKay

The University of Texas Health Science Center at Houston

UNITED STATES
View details

Xuelin Huang

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Lillian Kao

Professor, Chief of Acute Care Surgery

The University of Texas Health Science Center at Houston John P and Katherine G McGovern Medical School

UNITED STATES
View details

Christian Paige Owen

Assistant Professor

-

UNITED STATES
View details

Nils Johnson

Associate Professor of Medicine

McGovern Medical School at UTHealth

UNITED STATES
View details

Jack Tsai

Campus Dean and Professor

Yale University School of Medicine

UNITED STATES
View details